BTAI

BioXcel Therapeutics, Inc.
CAPPED RATING

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company which is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.

BioXcel Therapeutics, Inc. (BTAI) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Momentum (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
C+
Factor Score 2.7 / 5.0
Growth
B+
Factor Score 3.6 / 5.0
Profitability
B+
Factor Score 3.8 / 5.0
Momentum
F
Factor Score 0.6 / 5.0
Revisions
C
Factor Score 2.2 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.0
EV / EBITDA -2.1
Rev Growth YoY 51.7%
Gross Margin 53.1%
Price Return 3M -93.3%
Price Return 12M -97.9%
Catalyst Signal 0.00
Market Cap $2.3M
TTM Revenue $742.0K
Price / Sales 3.1
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-09-08 C+ (2.7) B+ (3.6) B+ (3.8) F (0.6) C (2.2) C+ (2.6)
2026-09-01 C+ (2.7) B+ (3.6) B+ (3.8) F (0.5) C (2.2) C+ (2.5)
2026-08-25 B- (2.9) B- (2.9) D (1.4) D- (0.9) C- (2.0) C- (2.0)
2026-08-18 B- (2.9) B- (2.9) D (1.4) D (1.2) C- (2.1) C- (2.1)
2026-08-05 C+ (2.7) C+ (2.7) D (1.3) C (2.4) C- (1.9) C (2.2)
Page 1 of 3